1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks

BACKGROUND: The pangenotypic direct-acting antivirals (DAAs) glecaprevir (developed by AbbVie and Enanta) coformulated with pibrentasvir (G/P) are approved as an 8-week regimen to treat chronic HCV infection for all six major genotypes (GT). An integrated analysis of patients treated with G/P for 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarrazin, Christoph, Tran, Tram, Dylla, Douglas, Feld, Jordan J, Arora, Sanjeev, Victor, David, Hu, Yiran B, Wang, Stanley, Mensa, Federico, Wyles, David L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253425/
http://dx.doi.org/10.1093/ofid/ofy210.1635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253425/
http://dx.doi.org/10.1093/ofid/ofy210.1635

Ejemplares similares